Dear Readers, Dear Authors, Dear Reviewers, We are living in unusual times and I am sure that you are all somewhat tired to hear about Corona again. But we have to acknowledge the impact it had on us on many levels and hope you have managed to stay clear of any infections, that you and your loved ones are safe and sound. The editorial team of ChemBioEng Reviews, although working from home since March, has done their best to keep business going as usual. Therefore, instead of dwelling on the difficulties (most news outlets are already doing that quite well), we would like to highlight some positive aspects of ChemBioEng Reviews that may lift our spirits and allow us to be thankful. Foremost, we proudly announce that ChemBioEng Reviews has finally received its first impact factor. Being anticipated for a long time, the result is quite an achievement: 3.83 is the highest IF among the Wiley Engineering portfolio and shows that the community values our contributions. But this has not been possible without your continuous support. We therefore would like to express our deepest gratitude for your loyalty and encouragement over the last years. Together we will succeed! Last year, we also talked about the agreement Wiley has signed with Project DEAL, allowing researchers from German institutions to publish OpenAccess without additional costs to them. While we are now in our second year, we can say that the agreement is successfully embraced. But it only applies to German institutions; what about the rest of our international contributors? As the publishing landscape continues to push for widespread free access to research, Wiley has followed up with a variety of OpenAccess deals with different countries. Besides the agreement in Germany, there also exist agreements with British, Dutch, Austrian, Hungarian, Norwegian, Swedish, Finnish, and American consortia, and many more are bound to follow. For a full list, please visit Wiley Author Services, keyword “Open Access”. That being said, we are always happy to receive your contributions, OpenAccess or otherwise. We are also curious to hear back from you, to know what you think of us, our topics, our website, and if we can improve somehow. If you have any suggestions, ideas or questions, please let us know, we will be very happy to discuss it with you. Email us at cben@wiley.com or follow us on our newly created Facebook page. With this, we leave you to discover and enjoy this newest issue of ChemBioEng Reviews. Stay safe and healthy! Yours sincerely, Cordula Buse (Deputy Editor) and Barbara Boeck (Editor-in-Chief) Cordula Buse Barbara Boeck
Read full abstract